Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833

被引:172
作者
vanAsperen, J
vanTellingen, O
Sparreboom, A
Schinkel, AH
Borst, P
Nooijen, WJ
Beijnen, JH
机构
[1] NETHERLANDS CANC INST,DEPT MOL BIOL,NL-1066 CX AMSTERDAM,NETHERLANDS
[2] SLOTERVAART HOSP,DEPT PHARM,NL-1066 EC AMSTERDAM,NETHERLANDS
关键词
paclitaxel (Taxol); SDZ PSC 833; oral bioavailability; P-glycoprotein; reversal agent;
D O I
10.1038/bjc.1997.530
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inhibition of intestinal P-glycoprotein might enhance the absorption of orally administered P-glycoprotein substrate drugs. We show here a 10-fold increased oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. These results encourage further research on the development of a clinically useful oral formulation of paclitaxel.
引用
收藏
页码:1181 / 1183
页数:3
相关论文
共 18 条
[1]  
BOESCH D, 1991, CANCER RES, V51, P4226
[2]   THE 3 MOUSE MULTIDRUG RESISTANCE (MDR) GENES ARE EXPRESSED IN A TISSUE-SPECIFIC MANNER IN NORMAL MOUSE-TISSUES [J].
CROOP, JM ;
RAYMOND, M ;
HABER, D ;
DEVAULT, A ;
ARCECI, RJ ;
GROS, P ;
HOUSMAN, DE .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (03) :1346-1350
[3]  
Dorr R T, 1994, Ann Pharmacother, V28, pS11
[4]  
EISEMAN JL, 1994, CANCER CHEMOTH PHARM, V34, P465, DOI 10.1007/BF00685656
[5]   Pharmacological considerations in the modulation of multidrug resistance [J].
Fisher, GA ;
Lum, BL ;
Hausdorff, J ;
Sikic, BI .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (06) :1082-1088
[6]  
FUJITA H, 1994, KAN TO KAGAKU RYOHO, V21, P653
[7]  
HARRIS JW, 1994, CANCER RES, V54, P4026
[8]   TAXANES - A NEW CLASS OF ANTITUMOR AGENTS [J].
HUIZING, MT ;
MISSER, VHS ;
PIETERS, RC ;
HUININK, WWT ;
VEENHOF, CHN ;
VERMORKEN, JB ;
PINEDO, HM ;
BEIJNEN, JH .
CANCER INVESTIGATION, 1995, 13 (04) :381-404
[9]   SDZ PSC-833, A NONIMMUNOSUPPRESSIVE CYCLOSPORINE - ITS POTENCY IN OVERCOMING P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE OF MURINE LEUKEMIA [J].
KELLER, RP ;
ALTERMATT, HJ ;
NOOTER, K ;
POSCHMANN, G ;
LAISSUE, JA ;
BOLLINGER, P ;
HIESTAND, PC .
INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (04) :593-597
[10]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6